Revenue at Top End of Guidance
Q4 revenues of $980.1 million were at the top end of guidance and relatively consistent with the prior year period, demonstrating stable top-line execution.
Shift Toward Higher‑Margin IT Consulting
IT consulting comprised 63% of Q4 revenue versus 59% a year ago, reflecting successful transition to higher-value technology and digital engineering solutions.
Strong Commercial Consulting Growth and Bookings
Commercial consulting revenue was $339.4 million, up 19.2% year-over-year; commercial consulting bookings were a record $444.4 million in the quarter with a commercial book-to-bill of 1.3x (TTM 1.2x).
Adjusted EBITDA Margin Above Expectations
Q4 adjusted EBITDA was $107.9 million and adjusted EBITDA margin was 11%, exceeding prior guidance and driven by a greater mix of commercial revenue.
Very Strong Free Cash Flow and Cash Deployment
Q4 free cash flow was $93.7 million (conversion ~87% of adjusted EBITDA), full-year free cash flow was $288.1 million (68.2% of adjusted EBITDA). The company repurchased $64.2 million of shares in the quarter and $170.1 million for the year, with ~$972 million remaining on a $1 billion authorization.
Strategic Quinox Acquisition to Expand Digital Engineering and Offshore Delivery
Signed definitive agreement to acquire Quinox for $290 million in cash; Quinox had ~ $100 million revenue in 2025 and is expected to grow low-to-mid teens in 2026, with adjusted EBITDA margin in the low-20% range and gross margins in the low‑40% area—adds offshore delivery centers in India and broadened solution capabilities.
Robust Federal Backlog and AI/GTM Momentum
Federal contract backlog ~ $3.0 billion (coverage ratio 2.5x TTM revenue). Company launched an 'AI Factory' and highlighted partnerships with Elastic, ServiceNow, Workday, Snowflake and others to capture AI- and platform-driven demand.
Capital Structure and Liquidity
At quarter end, cash and cash equivalents were $161.2 million and ~$455 million was available on the $500 million revolver, providing liquidity to fund Quinox and other initiatives.